Enlivex Therapeutics Ltd. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enlivex Therapeutics Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2023 to Q2 2024.
  • Enlivex Therapeutics Ltd. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $388K, a 24.1% decline year-over-year.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $1.95M, a 28.1% decline from 2022.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $2.71M, a 6.93% decline from 2021.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2021 was $2.91M, a 116% increase from 2020.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $388K -$123K -24.1% Apr 1, 2024 Jun 30, 2024 6-K 2024-08-30
Q2 2023 $511K Apr 1, 2023 Jun 30, 2023 6-K 2024-08-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.